Table 1

Clinical-pathological prognostic features of disease
Screen-detected (n = 161) vs. Symptomatic (n = 130) P value OR adjusted by tumor size
Mean age 56.33 ± 1.14 vs. 56.73 ± 1.18 N.S. 1.03 (0.99-1.05)
Mean size (cm) 1.62 + 0.14 vs. 2.68 + 0.15 p < 0.001 --
Lymph node positive 22.3% vs. 48.9% p < 0.001 0.54 (0.31-0.95)
Poorly differentiated tumors 33.1% vs. 39.7% N.S. 0.75 (0.47-1.20)
ER positive 87.8% vs. 57.4% p < 0.001 4.76 (2.50-9.09)
PR positive 73.1% vs. 36.4% p < 0.001 4.16 (2.43-7.14)
In situ carcinomas 11.4% vs.1.5% p < 0.001 6.25 (1.35-33.3)
Apoptosis 48.8% vs. 38.5% N.S. 1.53 (0.84-2.77)
Bcl-2 78.4% vs. 62.7% p < 0.01 1.92 (1.08-3.44)
c-erb-B2 14.6% vs. 26.3% p < 0.05 0.57 (0.15-0.97)
Ki67 46.7% vs. 52.5% N.S. 0.97 (0.57-1.63)
Delay Diagnosis- treatment (>30 days) 47.5% vs. 57% N.S. 0.75 (0.46-1.25)

ER: estrogen receptor, PR: progesterone receptor.

Redondo et al.

Redondo et al. BMC Cancer 2012 12:604   doi:10.1186/1471-2407-12-604

Open Data